QuantiFERON-CMV Cell-Mediated Immunity to Predict Post-Prophylaxis CMV Disease in D+/R- Kidney Transplant Recipients (Phase 3 Letermovir vs Valganciclovir Trial)

A blood test of CMV-specific immunity measured at the end of antiviral prophylaxis was poor at predicting which high-risk kidney transplant patients would later develop CMV disease.